Proteomic Discovery of Genistein Action in the Rat Mammary Gland

Overview

Journal J Proteome Res

Publisher American Chemical Society

Specialty Biochemistry

Date 2011 Jan 25

PMID 21254785

Citations 10

Authors

Jun Wang

Angela M Betancourt

James A Mobley

Coral A Lamartiniere

Affiliations

Soon will be listed here.

Abstract

Genistein, the primary isoflavone component of soy, consumed in diet during the prepubertal period suppresses chemically induced mammary cancer in rats. The current study used two-dimensional gel electrophoresis (2-DE)/MS-based proteomic technology to identify proteins responsible for genistein breast cancer protection In Vivo. Female offspring were exposed via lactating dams treated with 250 mg genistein/kg AIN-76A diet from days 1 to 21 postpartum (prepubertal period). Mammary glands were collected at 21 and 50 day of age and subjected to 2-DE/MS and immuno-blot analyses. Twenty-three proteins were determined to be differentially regulated (p < 0.05) and identified using 2-DE, followed by MALDI-TOF/TOF or LC-ESI-MS/MS. Five of these proteins were validated by immuno-blots. Annexin A2 was significantly increased at 21 days yet found to be decreased at 50 days. Fetuin B was found to be unchanged at day 21 but increased at day 50. Phosphoglycerate kinase 1 (PGK1) was unchanged at day 21 but decreased at day 50. Gelsolin was increased at day 21 but not at day 50. Protein disulfide-isomerase A3 (PDIA3) was decreased at day 21 and unchanged at day 50. Also, we found that vascular endothelial growth factor receptor 2 (VEGF-R2) and epidermal growth factor receptor (EGF-R) were decreased in mammary glands of 50-day-old rats treated prepubertally with genistein. This study demonstrates the usefulness of proteomics for the discovery of key proteins involved in signaling pathways to understand genistein mechanisms of action in breast cancer prevention.

Citing Articles

Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review.

Khan F, Singh P, Jamous Y, Ali S, Abdullah , Uddin S Cancers (Basel). 2023; 15(1).

PMID: 36612248 PMC: 9818426. DOI: 10.3390/cancers15010249.

Genistein Directly Represses the Phosphorylation of STAT5 in Lactating Mammary Epithelial Cells.

Tsugami Y, Wakasa H, Nishimura T, Kobayashi K ACS Omega. 2021; 6(35):22765-22772.

PMID: 34514247 PMC: 8427774. DOI: 10.1021/acsomega.1c03107.

Extracellular vesicles in the development of organ-specific metastasis.

Urabe F, Patil K, Ramm G, Ochiya T, Soekmadji C J Extracell Vesicles. 2021; 10(9):e12125.

PMID: 34295457 PMC: 8287318. DOI: 10.1002/jev2.12125.

Impairment of cell adhesion and migration by inhibition of protein disulphide isomerases in three breast cancer cell lines.

Young H, McGowan L, Jepson K, Adams J Biosci Rep. 2020; 40(10).

PMID: 33095243 PMC: 7584814. DOI: 10.1042/BSR20193271.

Soy-Based Therapeutic Baby Formulas: Testable Hypotheses Regarding the Pros and Cons.

Westmark C Front Nutr. 2017; 3:59.

PMID: 28149839 PMC: 5241282. DOI: 10.3389/fnut.2016.00059.

References

Lamartiniere C, Murrill W, Manzolillo P, Zhang J, Barnes S, Zhang X . Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Proc Soc Exp Biol Med. 1998; 217(3):358-64. DOI: 10.3181/00379727-217-44245. View

Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi R . Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res. 2009; 8(11):5041-7. DOI: 10.1021/pr900461c. View

Guo Y, Wang S, Colman R . Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol. 2001; 21(9):1427-33. DOI: 10.1161/hq0901.095277. View

Russo I, Russo J . Developmental stage of the rat mammary gland as determinant of its susceptibility to 7,12-dimethylbenz[a]anthracene. J Natl Cancer Inst. 1978; 61(6):1439-49. View

Syed S, Martin A, Haupt H, Arenas-Elliot C, Brooks J . Angiostatin receptor annexin II in vascular tumors including angiosarcoma. Hum Pathol. 2007; 38(3):508-13. DOI: 10.1016/j.humpath.2006.09.011. View

Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin H, Hayoz D . Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci. 2004; 61(19-20):2614-23. DOI: 10.1007/s00018-004-4225-6. View

Lay A, Jiang X, Kisker O, Flynn E, Underwood A, Condron R . Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature. 2000; 408(6814):869-73. DOI: 10.1038/35048596. View

Srinivas P, Wagner A, Reddy L, Deutsch D, Leon M, Goustin A . Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993; 7(11):1445-55. DOI: 10.1210/mend.7.11.7906861. View

Lamartiniere C . Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia. 2002; 7(1):67-76. DOI: 10.1023/a:1015722507237. View

10.

Fritz W, Coward L, Wang J, Lamartiniere C . Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis. 1999; 19(12):2151-8. DOI: 10.1093/carcin/19.12.2151. View

11.

Flynn K, Ferguson S, Delclos K, Newbold R . Effects of genistein exposure on sexually dimorphic behaviors in rats. Toxicol Sci. 2000; 55(2):311-9. DOI: 10.1093/toxsci/55.2.311. View

12.

Russo J, Russo I . Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994; 3(4):353-64. View

13.

Russo J, Wilgus G, Russo I . Susceptibility of the mammary gland to carcinogenesis: I Differentiation of the mammary gland as determinant of tumor incidence and type of lesion. Am J Pathol. 1979; 96(3):721-36. PMC: 2042395. View

14.

Sharma M, Sharma M . The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des. 2008; 13(35):3568-75. DOI: 10.2174/138161207782794167. View

15.

Thor A, Edgerton S, Liu S, Moore 2nd D, Kwiatkowski D . Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res. 2001; 7(8):2415-24. View

16.

Zhang D, Tai L, Wong L, Chiu L, Sethi S, Koay E . Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 2005; 4(11):1686-96. DOI: 10.1074/mcp.M400221-MCP200. View

17.

Rowell C, Carpenter D, Lamartiniere C . Chemoprevention of breast cancer, proteomic discovery of genistein action in the rat mammary gland. J Nutr. 2005; 135(12 Suppl):2953S-2959S. DOI: 10.1093/jn/135.12.2953S. View

18.

Hunter T, Cooper J . Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell. 1981; 24(3):741-52. DOI: 10.1016/0092-8674(81)90100-8. View

19.

MacMahon B, Cole P, Lin T, Lowe C, MIRRA A, RAVNIHAR B . Age at first birth and breast cancer risk. Bull World Health Organ. 1970; 43(2):209-21. PMC: 2427645. View

20.

Tanaka H, Shirkoohi R, Nakagawa K, Qiao H, Fujita H, Okada F . siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer. 2005; 118(7):1680-91. DOI: 10.1002/ijc.21559. View